Jonathan A. Ledermann

TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.

TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.

TL;DR: A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions as mentioned in this paper, and the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncologies (ESTRO), and the EPSP jointly decided to update these evidence-base guidelines and to cover new topics in order to improve the quality of care for women with endometrium carcinoma across Europe and worldwide.

TL;DR: The expanded use of PARP inhibitors in HRD deficient (non-BRCA mutant) tumours using a signature of HRD in clinical practice requires validation.

TL;DR: In this paper, the authors reviewed targeted approaches to therapy, focussing on targeting angiogenesis and inhibition of DNA repair, 2 areas that show promising activity. And they reviewed studies that are underway, targeting the cell cycle, signalling pathways and immunotherapeutic strategies.